SMX (Security Matters) Bolsa (NASDAQ: SMX)

Últimas noticias sobre SMX (Security Matters) (NASDAQ:SMX) Bolsa

SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHR

ATCH

ATPC

AVGR

CANG

CHCI

HCWC

LIDR

NMHI

PHIO

PIII

RGNX

RIME

SANG

STAF

URGN

YOSH

Las acciones de KB Home suben 9,1% tras superar expectativas de ganancias. Descubre los mayores ganadores y perdedores del mercado hoy.

Las acciones de KB Home se disparan un 9%; 20 acciones que se mueven en el premercado de EE.UU.

SMX (Security Matters) Public Limited Company - Class A Ordinary Shares

SMX (Security Matters) PLC

SolarMax Technology Inc

SMX (Security Matters) Public Limited Company - Warrant

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) became the first company valued at<a href="https://www.benzinga.com/markets/tech/25/07/46326271/nvidia-breaks-4-trillion-barrier-benzinga-poll-predicted-it-first"> more than $4 trillion</a>, passing the milestone in early July. The momentum continues through the end of the month with Nvidia hitting new all-time highs early Wednesday morning.
NVDA is holding near its annual highs. <a href="https://www.benzinga.com/quote/NVDA" target="_blank" rel="noreferrer noopener">Check the price action here.</a>
Here's a look back at how Nvidia CEO Jensen Huang celebrated a past company milestone and how much investors could have made with a less painful celebration along the way.
What Happened: Nvidia passed a market capitalization of <a href="https://www.benzinga.com/news/23/05/32630114/nvidia-becomes-ninth-company-to-hit-1-trillion-market-cap-who-could-be-next-to-join-elusive-club" target="_blank" rel="noreferrer noopener">$1 trillion in May 2023&nbsp;</a>and has taken the market by storm, passing multiple milestones since then, including the recent $4 trillion figure.
Nvidia is now worth $4.29 trillion and could be the first company to hit the $5 trillion market capitalization, according<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46395825/nvidia-vs-microsoft-vs-apple-who-will-hit-5-trillion-market-cap-first-75-of-readers-pick-this-stock"> to Benzinga readers.</a>
Huang<a href="https://www.benzinga.com/general/social-media/24/03/37879478/humble-beginnings-like-nvidia-reddit-was-founded-inside-a-restaurant" target="_blank" rel="noreferrer noopener">&nbsp;co-founded Nvidia in 1993&nbsp;</a>and still leads the company today. His wealth has soared along with the Nvidia stock price.
Before Nvidia hit a $1 trillion market cap, another milestone was hit years ago, with shares passing the $100 level. That level would be reached several times, with shares splitting multiple times since 2000.
To celebrate the occasion of shares hitting $100, Huang promised company executives he would get the Nvidia logo as a tattoo.
In a 2017&nbsp;<a href="https://fortune.com/2017/11/16/nvidia-ceo-jensen-huang/" target="_blank" rel="noreferrer noopener">interview&nbsp;</a>with Fortune, Huang revealed the tattoo and shared more details.
"So, I really want to extend it. I actually kinda do. I would love to. But getting it really, really hurt," Huang said.
Huang said his family was with him when he got his tattoo.
"I was crying like a baby. My kids were with me, and they were like, ‘Dad, you've gotta control yourself.&#8217;"
Huang mentioned that a semi-annual meeting from years ago was the inspiration behind the tattoo.
"And at one, someone said, ‘What are we gonna do when the stock price hits $100?&#8217;"
Huang recalled that others said they would shave their head, paint their hair a new color, get a mohawk and even get a nipple ring.
"So I said, ‘Yeah all right, I'll get a tattoo.&#8217;"
The first picture that can be found online of Huang's tattoo comes from the Nvidia Gaming Festival, with a post on Nvidia's&nbsp;<a href="https://www.instagram.com/nvidia/p/uli1ICDpSH/" target="_blank" rel="noreferrer noopener">Instagram&nbsp;</a>on Oct. 25, 2014.
"NVIDIA CEO Jen-Hsu Huang shows off his #NVIDIA tattoo at the NVIDIA Gaming Festival," the post reads.
It is unknown when Huang got his tattoo, but it doesn't sound like more will be added to his arms anytime soon.
"Aging gracefully. No more tattoos. It hurts way more than anybody tells you," Huang&nbsp;<a href="https://www.youtube.com/watch?v=8QcLkB-zdCU" target="_blank" rel="noreferrer noopener">said&nbsp;</a>in a 2023 interview.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Investing $1,000 in Nvidia Stock: With the date unknown for exactly when Huang got his tattoo, the starting point for this article will be for when the tattoo was unveiled to the public.
The Nvidia Instagram post with Huang's tattoo was shared on Oct. 25, 2014, which fell on the weekend. Shares opened at $18.48 on the following Monday.
A $1,000 investment at the time could have bought 54.11 NVDA shares. Nvidia stock split four-for-one in July 2021 and 10-for-1 in June 2024. This would have turned the initial share count into 2,164.40 shares.
The $1,000 investment would be worth $381,497.14 today. This represents a potential return of +38,049.7%.
Compare that to a $1,000 investment in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500. A $1,000 investment in the ETF on the same day could have bought 5.11 SPY shares at the time. The $1,000 investment would be worth $3,252.06 today, representing a potential return of 225.2%.
Another point of reference could have been to buy Nvidia shares after the Fortune interview, which labeled Huang the Businessperson of the Year and made the tattoo more of a storyline for the public.
A $1,000 investment could have purchased 4.67 shares of Nvidia on Nov. 16, 2017, at a price of $214.20. The stock splits would have turned the investment into 186.80 NVDA shares. The $1,000 investment would be worth $32,178.17 today, representing a return of 3,117.8%.
The same $1,000 invested in the SPDR S&amp;P 500 ETF Trust on the same date could have purchased 3.89 SPY shares, which would be worth $2,475.63. This represents a potential return of 147.6%.
Investors who followed Huang&#8217;s tattoo journey and recognized Nvidia&#8217;s potential for future milestones would be incredibly grateful today.
If Huang does decide to get a new tattoo to commemorate hitting $4 trillion or potentially a $5 trillion market cap, investors should take note.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/education/25/06/45983347/jensen-huang-gave-12-6-million-to-charity-then-nvidias-stock-made-it-billions">Jensen Huang Gave $12.6 Million To Charity, Then Nvidia&#8217;s Stock Made It Billions</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Photo: Image created from Shutterstock photos

Tech

NVDA

If You Invested $1,000 In Nvidia Stock When Jensen Huang Got Company Logo Tattoo, Here's How Much You'd Have Today

Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) will release its second-quarter 2025 financial <a href="https://www.benzinga.com/topic/pharmaceuticals">results tomorrow, July 30</a>.
According to <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, the company expects to report second-quarter earnings of 62 cents, with sales of <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">around $4.29 billion</a>.
Teva&#8217;s generics business has rebounded. The company saw a 5% increase in revenue across regions. Its top-three global portfolio may yield five new product launches by 2027.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45820489/goldman-sachs-bullish-on-branded-drug-upside-at-teva-what-about-viatris" target="_blank" rel="noreferrer noopener">Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?</a>
According to Piper Sandler, generic Revlimid won't matter much to the business after this year due to rising competition. However, it still plays a vital role in the U.S. generics segment.
The company's management expects the first quarter of 2025 to show the strongest year-over-year growth for its generics business.
They also noted that they usually sell most of their allowed amount of generic Revlimid in the second and third quarters.
Piper maintains an Overweight rating, increasing the <a target="_blank" href="https://www.benzinga.com/quote/TEVA/analyst-ratings" rel="noreferrer noopener">price forecast from $29 to $30</a>.
Additionally, settlements with other generic drugmakers will allow more competitors, including new ones, to enter the market and sell larger volumes in 2025.
Analyst David Amsellem questions whether total revenue for 2025 could be near the lower end of management's guidance <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">range of $16.8 billion-$17.2 billion</a>.
The analyst writes that since there is a possibility, Teva should not be penalized.
Austedo continues to grow steadily, with prescription volumes up approximately 19% year-to-date.
Uzedy is performing better than expected, with prescriptions increasing by about 21% in the second quarter of 2025 and 17% in the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" rel="noreferrer noopener">first quarter of 2025</a>.
Piper Sandler considers 2025 to be a low point for EBITDA, as cost-saving measures and efficiency improvements are expected to start benefiting profits in 2026.
Teva's branded drug business will also become more influential. A long-acting injectable version of olanzapine is launching in late 2026. It expects duvakitug by the end of the decade. And a $5 billion innovative medicines <a href="https://www.benzinga.com/general/biotech/25/05/45678673/teva-reaffirms-growth-strategy-eyes-5-billion-innovative-franchise-by-2030">franchise should be up and running by 2030</a>.
Additionally, Teva won't face major loss of exclusivity (LOE) issues until well into the 2030s. This supports the case for a higher valuation multiple.
Price Action: TEVA stock is down 0.09% at $16.50 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/07/46686877/drug-prices-to-get-more-expensive-under-trumps-eu-trade-deal-as-pharma-faces-billions-in-added-costs-report" target="_blank" rel="noreferrer noopener">Drug Prices To Get &#8216;More Expensive&#8217; Under Trump&#8217;s EU Trade Deal As Pharma Faces Billions In Added Costs</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Earnings

Large Cap

Guidance

Health Care

Analyst Ratings

General

TEVA

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

<a href="https://www.bloomberg.com/news/articles/2025-07-29/trump-floats-skipping-g-20-summit-citing-rift-with-south-africa">https://www.bloomberg.com/news/articles/2025-07-29/trump-floats-skipping-g-20-summit-citing-rift-with-south-africa</a>

'Trump Floats Skipping G-20 Summit, Citing Rift With South Africa'- Bloomberg

WIIM

Sysco shares are trading lower after the company issued FY26 adjusted EPS guidance below estimates.

Reuters Cites U.S. Ambassador To Canada Saying "Hopefully Very Soon" A Trade Deal Between Canada And U.S. Will Be Reached

Crane shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 adjusted EPS guidance.

CHTR

Charter Communications shares are trading lower after UBS cut its price target on the stock from $425 to $355.

Centene shares are trading lower after JP Morgan cut its price target on the stock from $48 to $30.

Cemex shares are trading higher after Barclays raised its price target on the stock from $9 to $10.

<a href="https://www.cnbc.com/2025/07/29/nike-loses-head-of-north-america-womens-business-to-athleta.html">https://www.cnbc.com/2025/07/29/nike-loses-head-of-north-america-womens-business-to-athleta.html</a>

'Nike loses head of North America women's business to Athleta'- CNBC

Citigroup analyst Ygal Arounian maintains Teads Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAD#NASDAQ">TEAD</a>) with a Neutral and lowers the price target from $3.9 to $3.4.

Price Target

TEAD

Citigroup Maintains Neutral on Teads Holding, Lowers Price Target to $3.4

Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>), one of the largest healthcare management companies in the U.S., reported second-quarter adjusted earnings of $5.35 per share on Monday.
The company, which oversees hundreds of behavioral health facilities, beat <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus of $4.92</a>.
The King of Prussia, Pennsylvania-based hospital operator reported sales of $4.28 billion, up 9.6% year over year, beating the consensus estimate of $4.24 billion.
Also Read: <a href="https://www.benzinga.com/markets/earnings/25/07/46632096/hca-healthcare-eyes-76-billion-revenue-aggressive-profit-growth" target="_blank" rel="noreferrer noopener">HCA Healthcare Eyes $76 Billion Revenue, Aggressive Profit Growth</a>
<h2 class="wp-block-heading">Acute care hospitals</h2>
During the second quarter of 2025, at acute care hospitals owned during both periods (on the same facility basis), adjusted admissions (adjusted for outpatient activity) increased by 2.0%, while adjusted patient days <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46673559/universal-health-services-inc-announces-financial-results-for-the-three-and-six-month-periods-ende" rel="noreferrer noopener">increased by 1.1% year over year</a>.
Net revenue per adjusted admission increased by 3.8% while net revenue per adjusted patient day increased by 4.7%.
Net revenues generated from acute care services, on a same facility basis, increased by 7.9%.
<h2 class="wp-block-heading">Behavioral health care facilities</h2>
During the second quarter of 2025, at behavioral health care facilities on a same-facility basis, adjusted admissions increased by 0.4%, while adjusted patient days increased by 1.2%.
Net revenue per adjusted admission increased by 8.6% and net revenue per adjusted patient day increased by 7.8%.
Net revenues generated from behavioral health care services, on a same facility basis, increased by 8.9%.
Universal Health operates 29 inpatient acute care hospitals and 338 inpatient behavioral health facilities, plus 61 outpatient facilities.
<h2 class="wp-block-heading">Guidance</h2>
Universal Health Services raised fiscal year 2025 adjusted earnings from $18.45-$19.95&nbsp;per share to&nbsp;$20.00-$21.00, compared to the consensus of&nbsp;$19.68.
The company narrowed 2025 sales&nbsp;guidance&nbsp;from&nbsp;$17.02 billion-$17.36 billion to&nbsp;$17.09 billion-$17.31 billion, versus the consensus of&nbsp;$17.14 billion.
UHS revised its 2025 forecasted adjusted EBITDA to approximately&nbsp;$2.46 billion—$2.543 billion, compared to the prior range of $2.36 billion—$2.48 billion.
<h2 class="wp-block-heading">Analyst Take</h2>
Guggenheim Partners said adjusted EBITDA-NCI of $643 million beat the consensus estimate of $615 million. However, the company's underlying "core" performance was weaker than expected after removing $101 million in DPP payments not included in the original guidance and a $25 million added headwind from DC hospitals. The shortfall was mainly due to underperformance in the Behavioral segment.
Analyst Jason Cassorla writes, &#8220;However, we believe higher 2025 EBITDA and subsequently FCF likely translates into higher share repurchase, all-else equal, and that leverage at 1.9x gives the company ample flexibility to continue augmenting returns.&#8221;
Analyst Cassorla expects the stock to trade unevenly following the results, despite a ~15% drop in the past two weeks (compared to a 2% gain in the S&amp;P 500) and UHS trading at historically low valuation levels. Investors remain cautious about future growth in the behavioral health segment due to ongoing challenges in patient volumes.
Price Action: UHS stock is up 4.86% at $162.49&nbsp;at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46687002/ups-volume-takes-a-hit-on-tariff-induced-weakness-withholds-annual-outlook" target="_blank" rel="noreferrer noopener">UPS Volume Takes A Hit On Tariff-Induced Weakness, Withholds Annual Outlook</a></li>
</ul>
Image: Shutterstock

Behavioral Segment Concerns Overshadow Universal Health Q2 Earnings Beat

Citigroup analyst Jon Tower maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Neutral and raises the price target from $180 to $197.

TXRH

Citigroup Maintains Neutral on Texas Roadhouse, Raises Price Target to $197

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and raises the price target from $41 to $46.

APLS

Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $46

APLS stock has given up its prior gain. Apellis Pharmaceuticals shares were trading higher after the company announced it has won FDA approval for EMPAVELI.

Citigroup analyst Peter Christiansen maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and raises the price target from $270 to $505.

COIN

Citigroup Maintains Buy on Coinbase Global, Raises Price Target to $505

Macro Notification

Politics

Economics

Live On CNBC, U.S. Treasury's Bessent On China Trade Says Tik Tok Not Discussed; Taiwanese Movements Not Part Of Talks; In 90 Days Don't Know Where We're Going To Be;  Good News Is We're Talking; Now We Have Communications At All Levels

Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) stock declined Tuesday as analysts reassessed its valuation despite ongoing <a href="https://www.benzinga.com/quote/TPR/analyst-ratings" target="_blank" rel="noreferrer noopener">strength in the Coach brand</a>.
Bank of America Securities analyst Lorraine Hutchinson downgraded Tapestry from Buy to Hold on Tuesday, raising the price forecast from $95 to $115.
Hutchinson observes that while the Coach brand is set to deliver several more quarters of strong growth, the stock's 66% year-to-date rally, far outpacing the S&amp;P's 9%, has brought its valuation close to fair value.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/07/46413056/tapestry-ups-investment-in-recycled-leather-pioneer-gen-phoenix" target="_blank" rel="noreferrer noopener">Coach Parent Tapestry Ups Investment In Recycled Leather Pioneer Gen Phoenix</a>
Over the past decade, Tapestry has traded at an average P/E of 13x, ranging between 6x and 20x, and is now sitting at the upper end of that range. As a result, she has moved to a Neutral stance, despite raising the price objective.
Hutchinson also anticipates a solid fourth quarter, forecasting EPS of 98 cents, matching management's guidance, and expects 5.4% sales growth and a 16.4% operating margin, while noting that a delayed Summer Sale may have boosted late-quarter sales, likely prompting an upbeat tone on the earnings call.
Hutchinson notes that fiscal year 2026 guidance will be closely watched, with expectations for mid-single-digit sales growth and stable margins, balancing tariff-related pressures with some SG&amp;A efficiency.
The analyst highlights that Coach continues to perform well, driven by successful marketing and premium product appeal, but doesn't foresee management forecasting double-digit growth for the brand this year.
While there's room for upside in fiscal year 2026 estimates, the analyst sees limited long-term margin expansion beyond Coach's already elevated 33.6% operating margin.
On tariffs, Hutchinson sees management can maintain profitability over time, though mitigation efforts will take a few quarters to ramp; the analyst projects a 60bp fiscal year 2026 gross margin decline from tariffs, with full recovery by fiscal year 2027, assuming initiatives scale and higher tariff rates accelerate those adjustments.
Price Action: TPR shares are trading lower by 2.35% to $107.83 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/25/04/44656550/grant-cardone-roasts-luxury-items-and-recommends-real-estate-instead-birkin-bags-are-not-investments" target="_blank" rel="noreferrer noopener">Grant Cardone Roasts Luxury Items and Recommends Real Estate Instead: ‘Birkin Bags Are Not Investments'</a></li>
</ul>
Image via Shutterstock

Equities

Downgrades

Why Tapestry Stock Is Cooling Off Despite Coach's Hot Streak

Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>), including a novel <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">therapeutic molecule, larsucosterol</a>.
Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for alcoholic hepatitis (AH) in Phase 2 trials.
Alcoholic hepatitis is&nbsp;a severe liver inflammation caused by excessive alcohol consumption.&nbsp;It is characterized by the rapid onset of jaundice and liver enlargement.
Bausch Health&#8217;s hepatology development and commercial capabilities are well-suited to support the clinical development and potential commercialization of larsucosterol.
The companies add that there is currently no Food and Drug Administration- or European Medicines Agency-approved treatment for AH.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45471704/icahn-ramps-up-bets-on-genes-and-jets-illumina-stake-jumps-450-jetblue-holding-grow-90" target="_blank" rel="noreferrer noopener">Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%</a>
Bausch Health will pay $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million, with the potential for two additional net sales milestone payments of up to $350 million.
A registrational Phase 3 program to evaluate the safety and efficacy of larsucosterol for the treatment of patients with severe AH is being planned.
The trial will be a randomized, double-blind, placebo-controlled, multi-center study. The primary endpoint will be 90-day survival.
The trial design will incorporate feedback received from the FDA during a Type B meeting under Breakthrough Therapy Designation and learnings from the prior Phase 2b AHFIRM trial in AH.
The acquisition of the clinical development program for larsucosterol in AH complements the ongoing Bausch Health RED-C clinical program, which is designed to assess the efficacy of a next-generation therapeutic, rifaximin SSD, to delay the onset of first overt hepatic encephalopathy (OHE) hospitalization and all-cause mortality.
Patient enrollment in two global Phase 3 studies is now complete with efficacy and safety results expected to be announced in early 2026.
The transaction is expected to close in the third quarter of 2025.
Last year, Bausch Health <a href="https://www.benzinga.com/news/large-cap/24/10/41313679/bausch-lomb-sale-process-gains-momentum-as-tpg-and-blackstone-join-forces" target="_blank" rel="noreferrer noopener">was in talks with several</a> private equity firms about selling Bausch + Lomb Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>).
The Bausch + Lomb spin-off was part of Bausch Health's plan to alleviate its $21 billion debt, a third&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40884021/contact-lens-supplier-bausch-lomb-eyes-sale-amid-separation-challenges-as-parent-bausch-health-fac" rel="noreferrer noopener">of which is due by 2027</a>.
BHC, DRRX Price Actions: Bausch Health stock is down 0.36% at $6.87, and DURECT stock is up 238.34% at $1.87 at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46688163/unitedhealth-misses-q2-mark-but-vows-a-healthier-2026" target="_blank" rel="noreferrer noopener">UnitedHealth Misses Q2 Mark But Vows A Healthier 2026</a></li>
</ul>
Photo: Shutterstock

BLCO

DRRX

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Rosenblatt analyst Kevin Cassidy maintains Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with a Buy and raises the price target from $80 to $90.

RMBS

Rosenblatt Maintains Buy on Rambus, Raises Price Target to $90

Press Releases

SMX-Powered Editorial on Supply Chain Risk Picked Up by Major National Outlet

SMX Establishes Treasury Subsidiary to Advance Digital Asset Strategy in Wake of GENIUS Act

trueGold Gives "Memory" to Gold - Jewelry & Watches Now Tell Their Own Story

Trump Lit the Match, SMX Is the Accelerant In The Newly Legitimized Digital Market

The GENIUS Act Just Launched a New Economy; SMX (Security Matters) Was Already There

SMX Is Opening the Sustainability Market for GenX and Millennial Investors

Penny Stocks

From Exclusive to Inclusive: SMX's PCT Brings the Value of Sustainable Assets to the New Age Investor

Peraso (NASDAQ: PRSO) Powers Military, Nex-Gen Broadband Surge – Mag 7 Undercard VAPE CELC, CRVO – More Stocks Inside

Stop the Corporate Rhetoric - SMX Makes Decarbonization Measurable, Not Marketing

Comments

SMX (Security Matters)

Noticias

Últimas noticias sobre SMX (Security Matters) (NASDAQ:SMX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL